| Aggregate Evidence Quality . | Grade C . |
|---|---|
| Benefits | Avoidance of unnecessary diagnostic evaluation |
| Risks, harm, cost | Potential to miss some children with secondary HTN |
| Benefit–harm assessment | Benefit equals harm |
| Intentional vagueness | Not applicable |
| Role of patient preferences | Some families may want further testing performed |
| Exclusions | Hypertensive children <6 y of age |
| Strength | Moderate recommendation |
| Key references | 16,129,235–240 |
| Aggregate Evidence Quality . | Grade C . |
|---|---|
| Benefits | Avoidance of unnecessary diagnostic evaluation |
| Risks, harm, cost | Potential to miss some children with secondary HTN |
| Benefit–harm assessment | Benefit equals harm |
| Intentional vagueness | Not applicable |
| Role of patient preferences | Some families may want further testing performed |
| Exclusions | Hypertensive children <6 y of age |
| Strength | Moderate recommendation |
| Key references | 16,129,235–240 |